author-photo

Alla Sergeevna Lisyanskaya

14

Papers

115

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

164 Phase 3 recurrent/metastatic cervical carcinoma trial: subgroup efficacy analysis of cemiplimab versus individual investigator’s choice chemotherapy

2021
Show All
- Source
- Cite
- Save
Citations (0)
Results of a completed first-in-human phase Ib dose-escalation study of oral CBL0137 in patients with advanced solid tumors.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (62)
843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in KEYNOTE-100

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Final results from the KEYNOTE-100 trial of pembrolizumab in patients with advanced recurrent ovarian cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
995PDTime to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Non-interventional study OVATAR final report: Diagnostic and treatment approaches in Russian ovarian cancer population—BRCAm group analysis.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)